CN105327007A - Pharmaceutical composition for treating hyperthyreosis - Google Patents
Pharmaceutical composition for treating hyperthyreosis Download PDFInfo
- Publication number
- CN105327007A CN105327007A CN201510893979.4A CN201510893979A CN105327007A CN 105327007 A CN105327007 A CN 105327007A CN 201510893979 A CN201510893979 A CN 201510893979A CN 105327007 A CN105327007 A CN 105327007A
- Authority
- CN
- China
- Prior art keywords
- squeezing juice
- parts
- herba
- squeezing
- juice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating hyperthyreosis. Ginkgo leaf tablets and fructus corni serve as main components, roses, eleusine indica, moleplant seeds, mulberries, camellia japonica, Chinese brake herbs, honeysuckle flowers and cucumbers are matched simultaneously, and the composition is prepared. According to an existing medical cognitive level, the components do not have direct promoting action on conditioning of an endocrine system or treatment of the hyperthyreosis; according to accident discoveries through experimental measures, the components are combined, the pharmaceutical composition which is obtained after optimization design is conducted on dosages of all the components can effectively treat the hyperthyreosis, the effect is taken rapidly, and the adverse reaction does not exist. On the basis of the positive discoveries, the pharmaceutical composition is obtained by an applicant; prominent technical effects are obtained through exquisite material selection and reasonable dosage design; meanwhile, the pharmaceutical composition is low in cost and easy to achieve, and the prominent popularizing prospect is achieved.
Description
Technical field
The present invention relates to treating endocrine diseases technical field, be specifically related to one and treat hyperthyroid pharmaceutical composition.
Background technology
Hyperthyroidism is called for short " hyperthyroidism ", is due to the too much thyroxin of thyroid synthesis release, causes the hyperfunction and sympathetic activation of organism metabolism, causes cardiopalmus, perspiration, feed and the just secondary disease increasing and lose weight.Most of patients also usually has the symptoms such as expophthalmos, blepharoedema, visual deterioration simultaneously.
Three kinds of method, i.e. Anti-thyroid Medicine, radioiodine therapy and operative treatments are mainly contained for Treatment of Hyperthyroidism in prior art.Wherein radioiodine therapy and operative treatment all belong to destructive treatment, treat successfully, not easily recur if it is advantageous that.But due to the former need to use radioiodine element, the latter needs open surgery, therefore all there is certain destructiveness to health, patient suffering's degree is comparatively large, and is difficult to bear and repeatedly treats.
On the other hand, Anti-thyroid Medicine wide accommodation, no matter age, course of disease length can adopt pharmacotherapy, and be even applicable to Hyperthyroidism Mothers, therefore its application is more extensive.In prior art, antithyroid drug mainly contains two classes, i.e. imidazoles and thiouracil class, represents medicine and is respectively thiamazole (thiamazole) and propylthiouracil (third is phonetic).But the defect of the Treatment of Hyperthyroidism medicine ubiquity length course for the treatment of of prior art, treatment is general needs 1 ~ 2 year, and needs over the course for the treatment of with thyroid function improvement situation adjustment drug dose.In addition, the Treatment of Hyperthyroidism medicine of prior art generally has certain side effect, comprises granulocytopenia, drug allergy, liver function damage, arthralgia and vasculitis etc., and this greatly adds treatment difficulty.Meanwhile, the Treatment of Hyperthyroidism medicine of prior art more lays particular emphasis on symptomatic treatment, and the opsonic action of Endocrine system running state is more weak, and therefore after drug withdrawal, relapse rate is high.
Summary of the invention
The present invention is intended to the technological deficiency for prior art, provides one to treat hyperthyroid pharmaceutical composition, with the technical problem that the Treatment of Hyperthyroidism curative effect of medication solving prior art is not good.
Another technical problem that the present invention solves is that the Treatment of Hyperthyroidism cured substance time of prior art is longer.
Another technical problem that the present invention solves is that the Treatment of Hyperthyroidism medicine of prior art easily untoward reaction occurs.
For realizing above technical purpose, the present invention by the following technical solutions:
One treats hyperthyroid pharmaceutical composition, comprise the composition of following weight portion: Folium Ginkgo squeezing juice 8 ~ 10 parts, Fructus Corni squeezing juice 4 ~ 6 parts, Flos Rosae Rugosae squeezing juice 2 ~ 3 parts, Herba Eleusines Indicae squeezing juice 1 ~ 2 part, Semen Euphorbiae squeezing juice 1 ~ 2 part, Fructus Mori squeezing juice 1 ~ 2 part, Flos Camelliae Japonicae squeezing juice 1 ~ 2 part, Herba Pteridis Multifidae squeezing juice 1 ~ 2 part, Flos Lonicerae squeezing juice 1 ~ 2 part, Fructus Cucumidis sativi squeezing juice 1 ~ 2 part.
Preferably, the Herba Cymbopogonis Citrari squeezing juice of 1 ~ 2 weight portion is also comprised.
Preferably, the Herba Saussureae Involueratae squeezing juice of 1 ~ 2 weight portion is also comprised.
Preferably, the Radix Oenotherae erythrosepalae squeezing juice of 1 ~ 2 weight portion is also comprised.
Preferably, the Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice of 1 ~ 2 weight portion is also comprised.
Preferably, described compositions is grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 9 parts, Fructus Corni squeezing juice 5 parts, Flos Rosae Rugosae squeezing juice 2.5 parts, Herba Eleusines Indicae squeezing juice 1.5 parts, Semen Euphorbiae squeezing juice 1.5 parts, Fructus Mori squeezing juice 1.5 parts, Flos Camelliae Japonicae squeezing juice 1.5 parts, Herba Pteridis Multifidae squeezing juice 1.5 parts, Flos Lonicerae squeezing juice 1.5 parts, Fructus Cucumidis sativi squeezing juice 1.5 parts.
Preferably, described compositions is grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 8.5 parts, Fructus Corni squeezing juice 5.5 parts, Flos Rosae Rugosae squeezing juice 2.1 parts, Herba Eleusines Indicae squeezing juice 1.3 parts, Semen Euphorbiae squeezing juice 1.7 parts, Fructus Mori squeezing juice 1.6 parts, Flos Camelliae Japonicae squeezing juice 1.2 parts, Herba Pteridis Multifidae squeezing juice 1.1 parts, Flos Lonicerae squeezing juice 1.4 parts, Fructus Cucumidis sativi squeezing juice 1.5 parts, Herba Cymbopogonis Citrari squeezing juice 1.4 parts, Herba Saussureae Involueratae squeezing juice 1.1 parts, Radix Oenotherae erythrosepalae squeezing juice 1.5 parts, Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice 1.8 parts.
In above technical scheme, Folium Ginkgo refers to the fresh blade of xylophyta Semen Ginkgo; Fructus Corni refers to the fresh fruit after plant Fructus Corni removal pit; Semen Euphorbiae is the seed of euphorbia plant, is a kind of common Chinese medicine; Herba Pteridis Multifidae, Herba Eleusines Indicae, Herba Cymbopogonis Citrari, Radix Oenotherae erythrosepalae, Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) refer to its respective fresh herb respectively; Flos Rosae Rugosae, Flos Camelliae Japonicae, Flos Lonicerae, Herba Saussureae Involueratae refer to the fresh flowers of its each composition respectively; And Fructus Mori and Fructus Cucumidis sativi and commercially available vegetables and fruits.The squeezing juice of each composition can utilize various method to obtain raw material squeezing above, and can be such as directly squeezed raw material by physical method, also can be first rub to squeeze again.
Natural medicinal ingredients selected by the present invention respectively has its conventional disease category in the prior art, and such as Fructus Corni is mainly used in nourishing the liver and kidney, arresting sweating leak-stopping; Folium Ginkgo is used for obstruction of collaterals by blood stasis, obstruction of qi in the chest and cardialgia, apoplectic hemiplegia, the diseases such as cough and asthma due to lung deficiency; Flos Lonicerae has outstanding heat-clearing toxin-expelling functions; And Flos Rosae Rugosae is mainly used in QI and blood regulating, the effect such as to set aside all worries, calm the nerves.That is the composition selected by the present invention is on existing medical science human-subject test, and Endocrine system, hyperthyroidism disease do not have directly treatment or opsonic action separately for they.In this case, applicant finds unexpectedly, mentioned component is integrated and each Ingredient Amount is optimized to the rear Chinese medicine composition obtained of design and effectively can nurse one's health endocrine dysfunction, reduce thyroid hormones level, and then play Treatment of Hyperthyroidism effect, and have rapid-action, the advantage such as have no adverse reaction.Further, the present invention found through experiments, and the basis of above-mentioned formula is added Herba Cymbopogonis Citrari, Herba Saussureae Involueratae, Radix Oenotherae erythrosepalae or Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) further and contributes to promoting therapeutic effect further.
Based on above-mentioned discovery actively, applicant obtains pharmaceutical composition of the present invention, and said composition obtains outstanding technique effect with selection cleverly and the design of rational consumption, simultaneously cost lower, be easy to realize, there is outstanding promotion prospect.
Detailed description of the invention
Below will be described in detail the specific embodiment of the present invention.In order to avoid too much unnecessary details, in the examples below to belonging to known structure or function will not be described in detail.Apart from outside definition, technology used in following examples and scientific terminology have the identical meanings generally understood with those skilled in the art of the invention.
Embodiment 1
One treats hyperthyroid pharmaceutical composition, be grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 8 parts, Fructus Corni squeezing juice 4 parts, Flos Rosae Rugosae squeezing juice 2 parts, Herba Eleusines Indicae squeezing juice 1 part, Semen Euphorbiae squeezing juice 1 part, Fructus Mori squeezing juice 1 part, Flos Camelliae Japonicae squeezing juice 1 part, Herba Pteridis Multifidae squeezing juice 1 part, Flos Lonicerae squeezing juice 1 part, Fructus Cucumidis sativi squeezing juice 1 part.
Embodiment 2
One treats hyperthyroid pharmaceutical composition, be grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 10 parts, Fructus Corni squeezing juice 6 parts, Flos Rosae Rugosae squeezing juice 3 parts, Herba Eleusines Indicae squeezing juice 2 parts, Semen Euphorbiae squeezing juice 2 parts, Fructus Mori squeezing juice 2 parts, Flos Camelliae Japonicae squeezing juice 2 parts, Herba Pteridis Multifidae squeezing juice 2 parts, Flos Lonicerae squeezing juice 2 parts, Fructus Cucumidis sativi squeezing juice 2 parts.
Embodiment 3
One treats hyperthyroid pharmaceutical composition, be grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 9 parts, Fructus Corni squeezing juice 5 parts, Flos Rosae Rugosae squeezing juice 2.3 parts, Herba Eleusines Indicae squeezing juice 1.8 parts, Semen Euphorbiae squeezing juice 1.5 parts, Fructus Mori squeezing juice 1.6 parts, Flos Camelliae Japonicae squeezing juice 1.7 parts, Herba Pteridis Multifidae squeezing juice 1.8 parts, Flos Lonicerae squeezing juice 1.2 parts, Fructus Cucumidis sativi squeezing juice 1.8 parts.
Embodiment 4
One treats hyperthyroid pharmaceutical composition, is grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 8.8 parts, Fructus Corni squeezing juice 5.4 parts, Flos Rosae Rugosae squeezing juice 2.7 parts, Herba Eleusines Indicae squeezing juice 1.2 parts, Semen Euphorbiae squeezing juice 1.2 parts, Fructus Mori squeezing juice 1.2 parts, Flos Camelliae Japonicae squeezing juice 1.5 parts, Herba Pteridis Multifidae squeezing juice 1.6 parts, Flos Lonicerae squeezing juice 1.4 parts, Fructus Cucumidis sativi squeezing juice 1.7 parts, Herba Cymbopogonis Citrari squeezing juice 1 part, Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice 1.1 parts.
Embodiment 5
One treats hyperthyroid pharmaceutical composition, is grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 9.4 parts, Fructus Corni squeezing juice 4.2 parts, Flos Rosae Rugosae squeezing juice 2.1 parts, Herba Eleusines Indicae squeezing juice 1.3 parts, Semen Euphorbiae squeezing juice 1.1 parts, Fructus Mori squeezing juice 1 part, Flos Camelliae Japonicae squeezing juice 2 parts, Herba Pteridis Multifidae squeezing juice 1.9 parts, Flos Lonicerae squeezing juice 1.2 parts, Fructus Cucumidis sativi squeezing juice 1.9 parts, Herba Saussureae Involueratae squeezing juice 1.3 parts, Radix Oenotherae erythrosepalae squeezing juice 1.2 parts, Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice 1.6 parts.
Embodiment 6
One treats hyperthyroid pharmaceutical composition, be grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 8.8 parts, Fructus Corni squeezing juice 5.4 parts, Flos Rosae Rugosae squeezing juice 2.7 parts, Herba Eleusines Indicae squeezing juice 1.2 parts, Semen Euphorbiae squeezing juice 1.2 parts, Fructus Mori squeezing juice 1.2 parts, Flos Camelliae Japonicae squeezing juice 1.5 parts, Herba Pteridis Multifidae squeezing juice 1.6 parts, Flos Lonicerae squeezing juice 1.4 parts, Fructus Cucumidis sativi squeezing juice 1.7 parts, Herba Cymbopogonis Citrari squeezing juice 1.5 parts.
Embodiment 7
One treats hyperthyroid pharmaceutical composition, be grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 9.2 parts, Fructus Corni squeezing juice 5.7 parts, Flos Rosae Rugosae squeezing juice 2.4 parts, Herba Eleusines Indicae squeezing juice 1.5 parts, Semen Euphorbiae squeezing juice 1.5 parts, Fructus Mori squeezing juice 1.7 parts, Flos Camelliae Japonicae squeezing juice 1.7 parts, Herba Pteridis Multifidae squeezing juice 1.2 parts, Flos Lonicerae squeezing juice 1.9 parts, Fructus Cucumidis sativi squeezing juice 2 parts, Radix Oenotherae erythrosepalae squeezing juice 1.8 parts.
Embodiment 8
One treats hyperthyroid pharmaceutical composition, be grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 8.5 parts, Fructus Corni squeezing juice 5.5 parts, Flos Rosae Rugosae squeezing juice 2.1 parts, Herba Eleusines Indicae squeezing juice 1.3 parts, Semen Euphorbiae squeezing juice 1.7 parts, Fructus Mori squeezing juice 1.6 parts, Flos Camelliae Japonicae squeezing juice 1.2 parts, Herba Pteridis Multifidae squeezing juice 1.1 parts, Flos Lonicerae squeezing juice 1.4 parts, Fructus Cucumidis sativi squeezing juice 1.5 parts, Herba Cymbopogonis Citrari squeezing juice 1.4 parts, Herba Saussureae Involueratae squeezing juice 1.1 parts, Radix Oenotherae erythrosepalae squeezing juice 1.5 parts, Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice 1.8 parts.
Embodiment 9
The present embodiment for investigate above embodiment 1, embodiment 8 pharmaceutical composition to the therapeutic effect of patients suffered from hyperthyroidism.
1 experimental subject
1.1 case selections: Stochastic choice hyperthyroid patient 110 example, and except thyroid storm, all patients except hyperthyroidism, without other chronic disease medical histories, without the cardiac disorder that hyperthyroidism causes.Wherein: man 38 example, female 72 example, disease time is 1 ~ 5 month, and patient's main clinical manifestation is expophthalmos, bulimia and arrhythmia, thyromegaly etc.
1.2 diagnostic criterias: 1. hypermetabolism sings and symptoms; 2. TSH level declines, and FT4, FT3 level raises.
1.3 experiment groupings: 110 routine patients are divided into matched group 37 example, embodiment 1 drug oral treatment group 37 example and embodiment 8 drug oral treatment group 36 example at random.Compare in sex, age, the state of an illness before three groups of patient treatments, no significant difference (P > 0.05), has comparability.
2 methods
2.1 Therapeutic Method:
In matched group: matched group patient gives methimazole treatment (0.6mg/kg/d, point 3 times oral).Medication after 1 ~ 3 month the state of an illness substantially controlled, heart rate drops to 80 ~ 90 times/min, and when blood T3, T4 also drop to normal, methimazole can decrement 1/3 ~ 1/2.It within three months, is a course for the treatment of.
In embodiment 1 drug oral treatment group: give embodiment 1 drug oral (300mg/kg/d, point 3 times oral).It within three months, is a course for the treatment of.
In embodiment 8 drug oral treatment group: give embodiment 8 drug oral (300mg/kg/d, point 3 times oral).It within three months, is a course for the treatment of.
2.2 Outcome measure: formulate with reference to " new Chinese medicine guideline of clinical investigations ".1. clinical cure: symptom, sign disappear completely, serum FT 3, FT4, TSH are all normal; 2. take a turn for the better: symptom, sign are alleviated, have two in serum FT 3, FT4, TSH at least normally; 3. not effective: symptom, sign, without being clearly better, have more than two extremely in serum FT 3, FT4, TSH.
3 results
Treat 3 months after-stage comparitive study: embodiment 1 drug oral treatment group, embodiment 8 drug oral treatment group all cases all complete the treatment of 3 months, and have 3 examples to exit because of agranulocytosis in matched group, complete the comparitive study of case in table 1.
Table 1 pharmaceutical composition of the present invention is used for the effect experimental of hyperthyroidism clinical treatment
Three groups of experimental datas compare, and the clinical cure rate of the embodiment of the present invention 1,8 medicine is apparently higher than matched group, and meanwhile, the incidence rate of the phenomenon that do not take effect after treatment is lower.
In addition, in untoward reaction, in matched group, there is the probability of 21.62% (8/37) to occur granulocytopenia phenomenon, wherein have 3 examples therefore to exit treatment in matched group, and embodiment 1,8 drug oral treatment group does not all find untoward reaction.
4. conclusion.
Above experimental result confirms that the present invention treats hyperthyroid pharmaceutical composition and has the advantages that decrement is fast, clinical cure rate is high, has no adverse reaction in test simultaneously, illustrates that medicine of the present invention is used for Treatment of Hyperthyroidism safe and effective.
Above embodiments of the invention have been described in detail, but described content is only preferred embodiment of the present invention, not in order to limit the present invention.All make in application range of the present invention any amendment, equivalent to replace and improvement etc., all should be included within protection scope of the present invention.
Claims (7)
1. the hyperthyroid pharmaceutical composition for the treatment of, it is characterized in that the composition comprising following weight portion: Folium Ginkgo squeezing juice 8 ~ 10 parts, Fructus Corni squeezing juice 4 ~ 6 parts, Flos Rosae Rugosae squeezing juice 2 ~ 3 parts, Herba Eleusines Indicae squeezing juice 1 ~ 2 part, Semen Euphorbiae squeezing juice 1 ~ 2 part, Fructus Mori squeezing juice 1 ~ 2 part, Flos Camelliae Japonicae squeezing juice 1 ~ 2 part, Herba Pteridis Multifidae squeezing juice 1 ~ 2 part, Flos Lonicerae squeezing juice 1 ~ 2 part, Fructus Cucumidis sativi squeezing juice 1 ~ 2 part.
2. compositions according to claim 1, characterized by further comprising the Herba Cymbopogonis Citrari squeezing juice of 1 ~ 2 weight portion.
3. compositions according to claim 1, characterized by further comprising the Herba Saussureae Involueratae squeezing juice of 1 ~ 2 weight portion.
4. compositions according to claim 1, characterized by further comprising the Radix Oenotherae erythrosepalae squeezing juice of 1 ~ 2 weight portion.
5. compositions according to claim 1, characterized by further comprising the Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice of 1 ~ 2 weight portion.
6. compositions according to claim 1, it is characterized in that described compositions is grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 9 parts, Fructus Corni squeezing juice 5 parts, Flos Rosae Rugosae squeezing juice 2.5 parts, Herba Eleusines Indicae squeezing juice 1.5 parts, Semen Euphorbiae squeezing juice 1.5 parts, Fructus Mori squeezing juice 1.5 parts, Flos Camelliae Japonicae squeezing juice 1.5 parts, Herba Pteridis Multifidae squeezing juice 1.5 parts, Flos Lonicerae squeezing juice 1.5 parts, Fructus Cucumidis sativi squeezing juice 1.5 parts.
7. compositions according to claim 1, it is characterized in that described compositions is grouped into by the one-tenth of following weight portion: Folium Ginkgo squeezing juice 8.5 parts, Fructus Corni squeezing juice 5.5 parts, Flos Rosae Rugosae squeezing juice 2.1 parts, Herba Eleusines Indicae squeezing juice 1.3 parts, Semen Euphorbiae squeezing juice 1.7 parts, Fructus Mori squeezing juice 1.6 parts, Flos Camelliae Japonicae squeezing juice 1.2 parts, Herba Pteridis Multifidae squeezing juice 1.1 parts, Flos Lonicerae squeezing juice 1.4 parts, Fructus Cucumidis sativi squeezing juice 1.5 parts, Herba Cymbopogonis Citrari squeezing juice 1.4 parts, Herba Saussureae Involueratae squeezing juice 1.1 parts, Radix Oenotherae erythrosepalae squeezing juice 1.5 parts, Herba Lysimachiae Clethroids (Radix Seu Herba Lysimachiae Clethroidis) squeezing juice 1.8 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893979.4A CN105327007A (en) | 2015-11-30 | 2015-11-30 | Pharmaceutical composition for treating hyperthyreosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893979.4A CN105327007A (en) | 2015-11-30 | 2015-11-30 | Pharmaceutical composition for treating hyperthyreosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105327007A true CN105327007A (en) | 2016-02-17 |
Family
ID=55277913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510893979.4A Pending CN105327007A (en) | 2015-11-30 | 2015-11-30 | Pharmaceutical composition for treating hyperthyreosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105327007A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904762A (en) * | 2018-09-13 | 2018-11-30 | 陕西中医药大学附属医院 | A kind of hyperthyroidism therapeutic agent |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104857330A (en) * | 2015-05-11 | 2015-08-26 | 耿世平 | Traditional Chinese medicine composition for promoting sputum excretion |
-
2015
- 2015-11-30 CN CN201510893979.4A patent/CN105327007A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104857330A (en) * | 2015-05-11 | 2015-08-26 | 耿世平 | Traditional Chinese medicine composition for promoting sputum excretion |
Non-Patent Citations (1)
| Title |
|---|
| 张文学等: "《临床常见病中西医最新诊疗》", 31 August 2001 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904762A (en) * | 2018-09-13 | 2018-11-30 | 陕西中医药大学附属医院 | A kind of hyperthyroidism therapeutic agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN104173726B (en) | Chinese medicine composition for postpartum recuperating and its preparation method and application | |
| CN101721537A (en) | Traditional Chinese medicine for treating rheumatic and rheumatoid arthritis | |
| CN103251859A (en) | Pharmaceutical composition for treating dermatopathy | |
| CN102614424A (en) | Traditional Chinese medicine for treatment of edema | |
| CN105327007A (en) | Pharmaceutical composition for treating hyperthyreosis | |
| CN102451427A (en) | Heart nursing pellets | |
| CN104435545B (en) | A kind of Chinese medicine preparation for treating caused by benzene leukopenia | |
| CN104383453B (en) | Treat the Chinese medicine of craniocerebral injury manic disorder | |
| CN104888149A (en) | Drug for treating cervical cancer and preparation method for drug | |
| CN101912566B (en) | Traditional Chinese medicine for treating palpitation | |
| CN103961477B (en) | The endo-medicine and its preparation method of preventing and treating nursing period at initial stage acute mastitis | |
| CN104383353B (en) | A kind of preparation method of medicine ink | |
| CN103768328A (en) | Medicinal magnetic plaster for treating tumors | |
| CN104107242B (en) | A kind of Chinese medicine composition for the treatment of hyperthyroidism and its production and use | |
| CN102228532B (en) | Composite medicament for treating acne | |
| CN100361677C (en) | Medicine for treating psoriasis and preventing its recurrence | |
| CN103816394B (en) | A kind of Chinese medicine for the treatment of syndrome of blood deficiency type postpartum pain of body | |
| CN103211977A (en) | Traditional Chinese medicine preparation used for treating hyperthyroidism | |
| CN107789606A (en) | One kind prevention anti-influenza Chinese medicine sachet of deficiency of yang matter | |
| CN103520459B (en) | Traditional Chinese medicine for treating stasis-blocking-channel type chest stuffiness and pains | |
| CN105582187A (en) | Traditional Chinese medicine composition formula for preventing and treating allergic dermatitis | |
| CN105497632A (en) | Chinese medicinal preparation for treat insomnia | |
| CN104306811B (en) | A kind of Chinese medicine composition for treating children's psoriasis vulgaris |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160217 |